HUL and GSK Consumer to terminate distribution agreement for OTC products

Must Read

The agreement was for brands such as Crocin, Eno, Iodex, Ostocalcium, Otrivin, and Sensodyne. The one-year notice period for termination shall commenced from November 9, 2022

New Delhi: FMCG major Hindustan Unilever Ltd (HUL) and healthcare firm GSK have mutually decided to terminate their agreement for selling GSK’s Over-the-Counter (OTC) and oral care products.

The agreement was for brands such as Crocin, Eno, Iodex, Ostocalcium, Otrivin, and Sensodyne.

These brands were distributed by GlaxoSmithKline Consumer.

After HUL acquired GlaxoSmithKline Consumer in 2020, it entered into a distribution agreement with GSK to sell these OTC and oral care products.

“The company, GSKAPL and GSKCPL have mutually agreed and expressed their intention to terminate the agreements with effect from 8th November 2023,” said HUL.

As per the agreements, the one-year notice period for termination shall commence from November 9, 2022, it added.

“This shall not have any material effect on the operations of the company,” it added.

In December 2018, GSK Consumer Healthcare announced its merger with HUL in an all-stock deal at a valuation of the Indian unit of GSK at Rs 31,700 crore.

+ posts
spot_img
Latest News

IRF Trusted Mark launches a retail education program in collaboration with Goa Institute of Management

The first programme to be launched under this partnership will be on Retail Marketing Strategy Bengaluru: The International Retail Forum (IRF)...

More Articles Like This